KLK3 and ovarian cancer: An unpublished study (NCT01620593) found a significant decrease of prostate-specific antigen (PSA) after treatment of prostate cancer patients with metformin, while, in ovarian cancer (NCT01579812) no changes in progression-free and overall survival were reported (www.clinicaltrials.gov).